# Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

> **NCT05614115** · PHASE1 · COMPLETED · sponsor: **University of Utah** · enrollment: 62 (actual)

## Conditions studied

- End-stage Kidney Disease
- Kidney Disease, Chronic
- Dialysis
- Diabetic
- Non-diabetic
- Kidney Dysfunction
- Kidney Failure
- Hemodialysis

## Interventions

- **DRUG:** Empagliflozin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05614115
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-21
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05614115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05614115, "Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05614115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*